NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
50 hedge funds and large institutions have $13.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 10 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
4% less funds holding
Funds holding: 52 → 50 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
42% less capital invested
Capital invested by funds: $22.9M → $13.3M (-$9.55M)
75% less call options, than puts
Call options by funds: $307K | Put options by funds: $1.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.3M |
| 2 |
B
Bailard
Foster City,
California
|
+$1.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$398K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$360K |
| 5 |
D.E. Shaw & Co
New York
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$2.27M |
| 2 |
PP
PDT Partners
New York
|
-$270K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$255K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$172K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$161K |
NBSE Hedge Fund Activity: Q1 2016 in Review
50 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2016, worth a combined $13.3M — down 42% from $22.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NBSE and 8 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.3M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $2.27M sold.
- 50 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2016, down from 52 in Q4 2015.
- Funds reported $13.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2016, down 42% quarter-over-quarter.
- 8 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2016 and 10 closed out, a net change of -2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2016 was Opaleye Management, an estimated $1.3M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2016 was Baker Bros. Advisors, an estimated $2.27M sold.
Based on aggregated 13F filings for Q1 2016.